Vigil Neuroscience(VIGL) - 2023 Q4 - Annual Results

Exhibit 99.1 Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP; - Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed Biotech Industr ...